Long-term follow-up from the phase 1/2a PLX120-03 study reported durable responses with single-agent plixorafenib (PLX8394/FORE8394) in BRAF-altered primary central nervous system tumors, with no evidence of cumulative adverse effects over extended treatment durations. The analysis presented at the Among patients with BRAF V600E–mutated, MAPK inhibitor–naive primary CNS tumors, objective response rates reached 80% in high-grade glioma and 50% in low-grade glioma or glioneuronal tumor cohorts, with 12-month and 24-month progression-free survival rates of 56% and 33%, respectively.